SAFETY DATA SHEET

Betamethasone / Clotrimazole Ointment Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Betamethasone / Clotrimazole Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : Organon & Co.
              30 Hudson Street, 33nd floor
              07302 Jersey City, New Jersey, U.S.A
   Telephone : 551-430-6000
   E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

1.4 Emergency telephone number
   215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1B : H360D: May damage the unborn child.
   Specific target organ toxicity - repeated exposure, Category 1 : H372: Causes damage to organs through prolonged or repeated exposure.
   Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Danger
   Hazard statements : H360D May damage the unborn child.
   H372 Causes damage to organs through prolonged or repeated exposure.
   H410 Very toxic to aquatic life with long lasting effects.
   Precautionary statements : Prevention:
P201  Obtain special instructions before use.
P264  Wash skin thoroughly after handling.
P273  Avoid release to the environment.
P280  Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313  IF exposed or concerned: Get medical advice/ attention.
P391  Collect spillage.

Hazardous components which must be listed on the label:
betamethasone

2.3 Other hazards
None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repr. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td>&gt;= 1 - &lt; 2,5</td>
</tr>
<tr>
<td></td>
<td>245-764-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>betamethasone</td>
<td>378-44-9</td>
<td>Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410</td>
<td>&gt;= 0,025 - &lt; 0,1</td>
</tr>
<tr>
<td></td>
<td>206-825-4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Betamethasone / Clotrimazole Ointment Formulation

Version 6.4  Revision Date: 10.10.2020  SDS Number: 610359-00013  Date of last issue: 23.03.2020  Date of first issue: 08.04.2016

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray  Alcohol-resistant foam  Carbon dioxide (CO2)  Dry chemical
5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.
Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.
SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe dust, fume, gas, mist, vapours or spray.
- Do not swallow.
- Avoid contact with eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
</table>

5 / 19
**SAFETY DATA SHEET**

Betamethasone / Clotrimazole Ointment Formulation

Version 6.4  Revision Date: 10.10.2020  SDS Number: 610359-00013  Date of last issue: 23.03.2020  Date of first issue: 08.04.2016

<table>
<thead>
<tr>
<th>Substance</th>
<th>23593-75-1</th>
<th>TWA</th>
<th>0.2 mg/m³ (OEB 2)</th>
<th>Internal</th>
</tr>
</thead>
<tbody>
<tr>
<td>clotrimazole</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td>betamethasone</td>
<td>Further information: Skin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
<td>Internal</td>
<td></td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>Oral (Secondary Poisoning)</td>
<td>9.33 mg/kg food</td>
</tr>
</tbody>
</table>

**8.2 Exposure controls**

**Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

**Personal protective equipment**

Eye protection: Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection: Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Combined particulates and organic vapour type (A-P)

**SECTION 9: Physical and chemical properties**

**9.1 Information on basic physical and chemical properties**

Appearance: Viscous semi-solid

Colour: No data available

Odour: No data available

Odour Threshold: No data available
## SAFETY DATA SHEET

**Betamethasone / Clotrimazole Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.4</td>
<td>10.10.2020</td>
<td>610359-00013</td>
<td>23.03.2020</td>
<td>08.04.2016</td>
</tr>
</tbody>
</table>

- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: Not applicable
- **Flammability (solid, gas)**: Not classified as a flammability hazard
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: Not applicable
- **Relative vapour density**: Not applicable
- **Relative density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
  - **Partition coefficient: n-octanol/water**: Not applicable
  - **Auto-ignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.

### 9.2 Other information
- **Flammability (liquids)**: No data available
- **Particle size**: Not applicable

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity
- Not classified as a reactivity hazard.
10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
- Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
  Method: Calculation method
- Acute dermal toxicity: Acute toxicity estimate: > 2.000 mg/kg
  Method: Calculation method

Components:
- clotrimazole:
  Acute oral toxicity: LD50 (Rat): 708 mg/kg
  LD50 (Mouse): 761 mg/kg
  LD50 (Rabbit): > 1.000 mg/kg
  Acute inhalation toxicity: LC50 (Rat): > 0.73 mg/l
    Exposure time: 4 h
    Test atmosphere: dust/mist
  Acute dermal toxicity: LD50 (Mouse): 923 mg/kg
- betamethasone:
  Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity
: LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation
Not classified based on available information.

**Components:**

**clotrimazole:**
Species : Rabbit
Result : No skin irritation

**betamethasone:**
Species : Rabbit
Result : Mild skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**clotrimazole:**
Species : Rabbit
Result : Mild eye irritation

**betamethasone:**
Species : Rabbit
Result : No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**betamethasone:**
Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**clotrimazole:**
Genotoxicity in vitro

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td>Chromosome aberration test in vitro</td>
<td>negative</td>
</tr>
<tr>
<td>In vitro micronucleus test</td>
<td>negative</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</td>
<td>Rat</td>
<td>Oral</td>
<td>negative</td>
</tr>
<tr>
<td>Mammalian spermatogonial chromosome aberration test (in vivo)</td>
<td>Hamster</td>
<td></td>
<td>negative</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity- Assessment

Weight of evidence does not support classification as a germ cell mutagen.

Betamethasone:

Genotoxicity in vitro

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
</tr>
<tr>
<td>In vitro mammalian cell gene mutation test</td>
<td>negative</td>
</tr>
<tr>
<td>Chromosome aberration test in vitro</td>
<td>positive</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)</td>
<td>Mouse</td>
<td>Oral</td>
<td>equivocal</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity- Assessment

Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

clotrimazole:

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>78 weeks</td>
<td>negative</td>
</tr>
</tbody>
</table>


Reproductive toxicity
May damage the unborn child.

Components:

clotrimazole:
Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: LOAEL: 50 mg/kg body weight
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 180 mg/kg body weight
Result: No effects on foetal development

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

betamethasone:
Effects on foetal development : Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
Result: Fetotoxicity, Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**  
Not classified based on available information.

**STOT - repeated exposure**  
Causes damage to organs through prolonged or repeated exposure.

**Components:**

**clotrimazole:**  
Target Organs: Liver, Kidney, Adrenal gland  
Assessment: May cause damage to organs through prolonged or repeated exposure.

**betamethasone:**  
Target Organs: Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland  
Assessment: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**clotrimazole:**  
Species: Rabbit  
LOAEL: 5 - 40 mg/kg  
Application Route: Skin contact  
Exposure time: 3 Weeks  
Target Organs: Skin  
Symptoms: Oedema, Fissuring, Necrosis, Redness

Species: Rat  
LOAEL: 10 mg/kg  
Application Route: Oral  
Exposure time: 18 Months  
Target Organs: Liver, Kidney, Adrenal gland

Species: Dog  
LOAEL: 25 mg/kg  
Application Route: Oral  
Exposure time: 6 - 12 Months  
Target Organs: Adrenal gland  
Symptoms: Salivation, Lachrymation, Vomiting

**betamethasone:**
SAFETY DATA SHEET
Betamethasone / Clotrimazole Ointment Formulation

Version 6.4  Revision Date: 10.10.2020  SDS Number: 610359-00013  Date of last issue: 23.03.2020  Date of first issue: 08.04.2016

Species: Rabbit
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 10 - 30 d
Target Organs: Pituitary gland, Immune system, muscle

Species: Rat
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus gland

Species: Mouse
LOAEL: 0.1 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus gland

Species: Dog
LOAEL: 0.05 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Blood, thymus gland, Adrenal gland

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

clotrimazole:
Skin contact: Symptoms: Rash, Itching, Blistering, Oedema, Redness
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

betamethasone:
Inhalation: Target Organs: Adrenal gland
Skin contact: Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

clotrimazole:
Toxicity to fish: LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.02 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic: EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l
### Toxicity to microorganisms

**Test Type**: Respiration inhibition  
**Method**: OECD Test Guideline 209  
**EC50**: > 10,000 mg/l  
**Exposure time**: 3 h  
**Species**: Onchorhynchus mykiss (rainbow trout)

### Toxicity to fish (Chronic toxicity)

**NOEC**: 0,025 mg/l  
**Exposure time**: 32 d  
**Species**: Oncorhynchus mykiss (rainbow trout)  
**Method**: OECD Test Guideline 210

### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

**NOEC**: 0,01 mg/l  
**Exposure time**: 21 d  
**Species**: Daphnia magna (Water flea)  
**Method**: OECD Test Guideline 211

### M-Factor (Chronic aquatic toxicity)

: 10

### betamethasone:

#### Toxicity to algae/aquatic plants

**EC50** (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l  
**Exposure time**: 72 h  
**Method**: OECD Test Guideline 201  
**Remarks**: No toxicity at the limit of solubility  
**NOEC** (Pseudokirchneriella subcapitata (green algae)): 34 mg/l  
**Exposure time**: 72 h  
**Method**: OECD Test Guideline 201  
**Remarks**: No toxicity at the limit of solubility

#### Toxicity to fish (Chronic toxicity)

**NOEC**: 0,052 mg/l  
**Exposure time**: 32 d  
**Species**: Pimephales promelas (fathead minnow)  
**Method**: OECD Test Guideline 210  
**NOEC**: 0,07 µg/l  
**Exposure time**: 219 d  
**Species**: Oryzias latipes (Japanese medaka)  
**Method**: OECD Test Guideline 229

#### Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

**NOEC**: 8 mg/l  
**Exposure time**: 21 d
ic toxicity) Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 1.000

12.2 Persistence and degradability

**Components:**

**clotrimazole:**
Stability in water: Hydrolysis: 50% (242 d)

12.3 Bioaccumulative potential

**Components:**

**betamethasone:**
Partition coefficient: \( \log \text{Pow} = 2.11 \)

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

**SECTION 13: Disposal considerations**

13.1 Waste treatment methods

**Product:** Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information**

14.1 UN number

**ADN:** UN 3077
**ADR:** UN 3077
**RID:** UN 3077
**IMDG:** UN 3077
**IATA:** UN 3077
14.2 UN proper shipping name

**ADN**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, clotrimazole)

**ADR**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, clotrimazole)

**RID**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, clotrimazole)

**IMDG**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(betamethasone, clotrimazole)

**IATA**: Environmentally hazardous substance, solid, n.o.s.
(betamethasone, clotrimazole)

14.3 Transport hazard class(es)

**ADN** : 9
**ADR** : 9
**RID** : 9
**IMDG** : 9
**IATA** : 9

14.4 Packing group

**ADN**
- Packing group : III
- Classification Code : M7
- Hazard Identification Number : 90
- Labels : 9

**ADR**
- Packing group : III
- Classification Code : M7
- Hazard Identification Number : 90
- Labels : 9
- Tunnel restriction code : (-)

**RID**
- Packing group : III
- Classification Code : M7
- Hazard Identification Number : 90
- Labels : 9

**IMDG**
- Packing group : III
- Labels : 9
- EmS Code : F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo) : 956
14.5 Environmental hazards

**ADN**
Environmentally hazardous : yes

**ADR**
Environmentally hazardous : yes

**RID**
Environmentally hazardous : yes

**IMDG**
Marine pollutant : yes

**IATA (Passenger)**
Environmentally hazardous : yes

**IATA (Cargo)**
Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

- **AICS** : not determined
- **DSL** : not determined
- **IECSC** : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
SAFETY DATA SHEET

Betamethasone / Clotrimazole Ointment Formulation

Version 6.4  Revision Date: 10.10.2020  SDS Number: 610359-00013  Date of last issue: 23.03.2020  Date of first issue: 08.04.2016

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-statements

H302: Harmful if swallowed.
H311: Toxic in contact with skin.
H319: Causes serious eye irritation.
H330: Fatal if inhaled.
H360D: May damage the unborn child.
H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure.
H373: May cause damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
Eye Irrit.: Eye irritation
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous
GOODS BY RAIL; SADT - SELF-ACCELERATING DECOMPOSITION TEMPERATURE; SDS - SAFETY DATA SHEET; SVHC - SUBSTANCE OF VERY HIGH CONCERN; TCSI - TAIWAN CHEMICAL SUBSTANCE INVENTORY; TSCA - TOXIC SUBSTANCES CONTROL ACT (UNITED STATES); UN - UNITED NATIONS; UNRTDG - UNITED NATIONS RECOMMENDATIONS ON THE TRANSPORT OF DANGEROUS GOODS; vPvB - VERY PERSISTENT AND VERY BIOACUMULATIVE

FURTHER INFORMATION


Classification of the mixture:

<table>
<thead>
<tr>
<th></th>
<th>Classification procedure:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repr. 1B</td>
<td>H360D</td>
</tr>
<tr>
<td>STOT RE 1</td>
<td>H372</td>
</tr>
<tr>
<td>Aquatic Chronic 1</td>
<td>H410</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

ZA / EN